J&J, Legend's Carvykti delivers encouraging early growth ahead of key myeloma readout
In hot pursuit of Bristol Myers Squibb and 2seventy bio’s first-to-market Abecma, Johnson & Johnson and Legend Biotech’s CAR-T therapy Caryvkti has shown an encouraging sign of growth. | In hot pursuit of Bristol Myers Squibb and 2seventy bio’s first-to-market Abecma, Johnson & Johnson and Legend Biotech’s CAR-T therapy Caryvkti has shown an encouraging sign of growth.
